Caplacizumab for immune thrombotic thrombocytopenic purpura: real-world multicenter data

Gavriilaki, E; Nikolousis, E; Koravou, EE; Dimou-Besikli, S; Kartsios, C; Papakonstantinou, A; Mpanti, A; Pontikoglou, C; Kalpadaki, C; Bitsani, A; Tassi, I; Touloumenidou, T; Chatziconstantinou, T; Papathanasiou, M; Syrigou, A; Ztriva, E; Kaiafa, G; Mandala, E; Mellios, Z; Karakasis, D; Kourakli, A; Symeonidis, A; Kapsali, E; Papadaki, HH; Lalayanni, C; Sakellari, I

Gavriilaki, E (通讯作者)，G Papanicolaou Hosp, Dept Hematol, BMT Unit, Thessaloniki, Greece.

FRONTIERS IN MEDICINE, 2023; 10 ():

Abstract

Given the limited real-world data of caplacizumab, our multicenter real-world study was designed to assess the safety and efficacy of caplacizumab in ......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索